CLNN
Clene Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.85
−3.63%Year over year
Reported trailing growth
- Revenue
- -31.1%
- EBITDA
- -10.0%
- EBIT
- +23.1%
- EPS
- +12.0%
- Free cash flow
- +9.5%
- Operating cash flow
- +9.7%
Forward estimates
Based on analyst estimates
- Revenue
- +26.9%
- EBITDA
- +15.9%
- EPS
- +37.1%
Three-year CAGR
- Revenue
- -24.9%
- EBITDA
- +34.7%
- EBIT
- +30.2%
- Net income
- +33.6%
- EPS
- +53.3%
- Free cash flow
- +12.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026